drugset / Trial / NCT00879021

Study of Pregabalin in the Prevention of Central Neuropathic Pain in Acute Spinal Cord Injury

NCT00879021

Phase 3 Terminated 5 enrolled Nova Scotia Health Authority
RandomizedParallel-groupTriple-blindPrevention

Summary

This research study will test to see if people who receive pregabalin after their spinal cord injury will develop less nerve damage pain than people who do not receive it.

Timeline

Start
2009-09
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pregabalin Small molecule 150 mg Oral

Indications